Altre lingue Jiangsu Kanion Pharmaceutical Co.,Ltd.

Azioni

600557

CNE000001CL7

Prezzo di chiusura Shanghai S.E. Altri mercati azionari 00:00:00 06/05/2024			Variaz. 5gg	Var. 1 gen.
20,2 ^CNY	+2,96%		+2,02%	-1,56%

25/04	Jiangsu Kanion Pharmaceutical Co.,Ltd. Piano di riacquisto di azioni prorogato fino al 5 febbraio 2025.	CI
12/04	Jiangsu Kanion Pharmaceutical Co.,Ltd. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Jiangsu Kanion Pharmaceutical Co.,Ltd. Equity Buyback Plan Extended till February 5, 2025.	25/04
Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	12/04
Tranche Update on Jiangsu Kanion Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on February 7, 2024.	02/04
Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	10/03
Jiangsu Kanion Pharmaceutical Co.,Ltd. announces an Equity Buyback for CNY 150 million worth of its shares.	07/02
Jiangsu Kanion Pharmaceutical Co.,Ltd. authorizes a Buyback Plan.	06/02
Kanion Pharmaceutical's Jinzhen Oral Liquid Shows Positive Result in Clinical Trial	08/12
Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	25/10/23
Jiangsu Kanion Pharmaceutical Co.,Ltd.(XSSC:600557) added to S&P Global BMI Index	18/09/23
Kanion Pharmaceutical Gets Clinical Trial Nod in China for Pain Medicine	11/09/23
Kanion Pharmaceutical Wins Chinese Drug Regulator's Nod to Trial Wubie Huangui Granules	04/09/23
Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	12/07/23
Kanion Pharma Wins FDA Nod to Trial Myeloma Treatment Candidate in US	27/06/23
Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	07/04/23
Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	20/02/23
Kanion Pharma’s Common Cold Drug Included in China’s Medical Insurance Catalog	19/01/23
Jiangsu Kanion Pharma Gets Nod for Anti-Cancer Injection Trial	11/01/23
Jiangsu Kanion Pharma Gets Regulatory Nod for Traditional Chinese Medicine's Registration	30/12/22
Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	09/10/22
Jiangsu Kanion Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	31/08/22

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Jiangsu Kanion Pharmaceutical Co.,Ltd.

Azioni

600557

CNE000001CL7

Altre lingue

Filtri